Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.
Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or
deliver tumor-killing substances to them without harming normal cells. Drugs used in
chemotherapy, such as vinorelbine, work in different ways to stop tumor cells from dividing
so they stop growing or die. Combining vaccine therapy with monoclonal antibody therapy and
chemotherapy may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving vaccine therapy together with
trastuzumab and vinorelbine works in treating women with locally recurrent or metastatic
breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
UNC Lineberger Comprehensive Cancer Center
Collaborators:
National Cancer Institute (NCI) Susan G. Komen Breast Cancer Foundation